tiprankstipranks
Blurbs

Talaris Therapeutics (TALS) Gets a Hold from SVB Securities

In a report released on November 10, Mani Foroohar from SVB Securities assigned a Hold rating to Talaris Therapeutics (TALSResearch Report), with a price target of $2.00. The company’s shares closed last Friday at $1.53.

According to TipRanks, Foroohar is an analyst with an average return of -12.4% and a 44.55% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Rocket Pharmaceuticals, and Moderna.

Talaris Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $6.67.

See Insiders’ Hot Stocks on TipRanks >>

TALS market cap is currently $63.84M and has a P/E ratio of -0.90.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TALS in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.

Read More on TALS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles